Evidence map›Paper›PMID 41431485›Full record

ArticleCureus2025

Long-Term Renal Outcomes Among COVID-19 ICU Survivors Admitted With Acute Kidney Injury.

Rocio Rimachi, Hassane Ndjimi, Keitiane Kaefer, Antonella Cudia, Pierre Foulon, Daniel De Backer

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rocio RimachiIntensive Care Unit, CHIREC Hospitals, Brussels, BEL.
Hassane NdjimiDepartment of Intensive Care, Erasme University Hospital, Brussels, BEL.
Keitiane KaeferIntensive Care Unit, Brugmann University Hospital, Brussels, BEL.
Antonella CudiaIntensive Care Unit, CHIREC Hospitals, Brussels, BEL.
Pierre FoulonIntensive Care Unit, CHIREC Hospitals, Brussels, BEL.
Daniel De BackerIntensive Care Unit, CHIREC Hospitals, Brussels, BEL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Acute kidney injury (AKI) is associated with poor outcomes in intensive care unit (ICU) patients with COVID-19. The need for renal replacement therapy (RRT) was frequently reported among these patients. However, the long-term prognosis of new-onset AKI detected on ICU admission is not well defined, in opposition to AKI occurring at any time during ICU stay. We evaluated the long-term outcomes of early-AKI (present on admission) in COVID patients requiring ICU during the pandemic; identified AKI risk factors and the impact of RRT on survival and renal outcomes (short and long term).  Methods We conducted an observational study with retrospective analysis charts of COVID-19 adult patients consecutively admitted to the ICU at CHIREC Hospital, Brussels, Belgium, between March 2020 and April 2021. AKI criteria were assessed using KDIGO (Kidney Disease Improving Global Outcomes) criteria at baseline and daily during ICU stay. The data are reported at admission, at the time of the worst AKI stage, at ICU discharge, and at long-term follow-up 3.5 years after ICU discharge. Results Among the 247 COVID-19 patients admitted to the ICU, 236 were included in the analysis. Early AKI was detected in 87 (37%) patients. Age, acute respiratory distress syndrome, hypertension, diabetes, and obesity were significantly associated with the development of AKI. Sixty (69%) patients were in stage 1, nine (10%) in stage 2, and 18 (21%) in stage 3. Among patients with early AKI, 52 survived to the ICU, and 47 were available for long-term follow-up. ICU mortality was higher in patients with AKI stage 3 (66%) than those with AKI stage 1 (32%), and this mortality increased with AKI progression and the need for renal replacement therapy (RRT). In the early-AKI group, 22 patients (25%) required RRT during ICU stay, two (9%) received RRT at admission, while 20 (90%) received RRT during ICU stay. Among these 22 patients, 19 (86%) died in the ICU, while three (13%) survived to follow-up and were able to discontinue RRT.  Conclusions Early AKI is common in COVID-19 ICU patients with acute respiratory failure and is associated with increased ICU length of stay compared with that of no-AKI patients. Patients with poor progression of AKI during their ICU stay and those with RRT requirements have a high mortality rate; however, survivors generally experience sufficient renal recovery to discontinue RRT. Early-AKI survivors without RRT requirements show excellent recovery of renal function.

Indexed as

acute kidney injurycovid-19long-term outcomesrenal replacement therapysevere respiratory failure

Identifiers

PMID41431485
PMCPMC12718430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.